Pluri (PLUR) Competitors $5.31 -0.10 (-1.85%) Closing price 07/11/2025 03:49 PM EasternExtended Trading$5.51 +0.20 (+3.75%) As of 07/11/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCTShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Cybin Voyager Therapeutics I-Mab Alpha Cognition Lifevantage Journey Medical Innate Pharma Enanta Pharmaceuticals Spero Therapeutics Nuvectis Pharma Cybin (NYSE:CYBN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Which has stronger valuation and earnings, CYBN or PLUR? Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$3.88-1.97Pluri$330K125.99-$20.89M-$5.53-0.96 Do analysts recommend CYBN or PLUR? Cybin currently has a consensus target price of $85.00, suggesting a potential upside of 1,012.57%. Pluri has a consensus target price of $12.00, suggesting a potential upside of 125.99%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, CYBN or PLUR? Cybin has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Do insiders & institutionals hold more shares of CYBN or PLUR? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 25.9% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is CYBN or PLUR more profitable? Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Pluri -2,563.29%-4,191.91%-85.40% Does the media prefer CYBN or PLUR? In the previous week, Cybin had 1 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Cybin and 2 mentions for Pluri. Pluri's average media sentiment score of 0.62 beat Cybin's score of 0.17 indicating that Pluri is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCybin beats Pluri on 10 of the 16 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.56M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-0.9620.8528.2620.26Price / Sales125.99303.05437.10166.10Price / CashN/A42.1137.1257.67Price / Book5.317.638.045.49Net Income-$20.89M-$55.05M$3.19B$250.45M7 Day Performance-7.65%8.43%3.62%4.79%1 Month Performance20.96%8.14%5.98%9.59%1 Year Performance-7.48%1.62%29.39%16.41% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri3.4054 of 5 stars$5.31-1.8%$12.00+126.0%-7.5%$41.56M$330K-0.96150CYBNCybin2.7421 of 5 stars$7.70-2.2%$86.00+1,017.5%N/A$176.13MN/A-1.7550Analyst ForecastVYGRVoyager Therapeutics3.977 of 5 stars$3.15+3.6%$13.39+325.1%-60.2%$173.82M$80M-2.15100IMABI-Mab2.8936 of 5 stars$2.13+1.7%$6.00+182.4%+23.8%$173.53M$3.89M0.00380Analyst ForecastGap DownACOGAlpha Cognition1.7339 of 5 stars$10.75-4.4%$20.00+86.0%N/A$172.22MN/A-8.96N/ALFVNLifevantage4.3373 of 5 stars$13.43-1.2%$30.50+127.1%+96.7%$169.02M$200.16M19.46260DERMJourney Medical1.9834 of 5 stars$7.23+1.8%$9.50+31.4%+26.3%$165.55M$56.13M-18.2290IPHAInnate Pharma2.6291 of 5 stars$1.79-1.6%$11.00+514.5%-21.7%$165.00M$21.77M0.00220ENTAEnanta Pharmaceuticals3.9163 of 5 stars$7.77-1.5%$18.00+131.7%-59.0%$164.26M$67.64M-1.69160Positive NewsSPROSpero Therapeutics3.9703 of 5 stars$2.94+1.2%$5.00+70.4%+98.6%$164.10M$47.98M-2.29150NVCTNuvectis Pharma3.3682 of 5 stars$7.82-0.4%$17.00+117.5%+19.8%$163.36MN/A-6.928Positive News Related Companies and Tools Related Companies Cybin Competitors Voyager Therapeutics Competitors I-Mab Competitors Alpha Cognition Competitors Lifevantage Competitors Journey Medical Competitors Innate Pharma Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Nuvectis Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
